Skip to main content
Morepen Laboratories Ltd. logo

Morepen Laboratories Ltd. — Investor Relations & Filings

Ticker · MOREPENLAB ISIN · INE083A01026 LEI · 335800OJZDFHFQJ4HP35 BSE.NS Manufacturing
Open in API
Filings indexed 1,660 across all filing types
Latest filing 2025-05-13 Notice of Dividend Amou…
Country IN India
Listing BSE.NS MOREPENLAB

About Morepen Laboratories Ltd.

https://www.morepen.com

Morepen Laboratories Ltd. is a research-led company specializing in the development, manufacturing, and marketing of Active Pharmaceutical Ingredients (APIs), home diagnostic devices, and finished formulations. The company maintains a significant global presence, exporting high-quality APIs such as Loratadine, Montelukast, Atorvastatin, and Fexofenadine to numerous international markets. Its diagnostic division, branded as Dr. Morepen, is a prominent player in the home healthcare segment, offering a wide range of products including digital glucometers, blood pressure monitors, and nebulizers. Morepen operates manufacturing facilities compliant with international regulatory standards, including USFDA approvals. The company focuses on leveraging its R&D capabilities to deliver healthcare solutions and maintains a diverse portfolio across various therapeutic areas including cardiovascular, anti-diabetic, and anti-asthmatic treatments.

Recent filings

Filing Released Lang Actions
Please find enclosed press release.
Notice of Dividend Amount Classification · 95% confidence The document is a press release dated May 13, 2025, announcing that Morepen Laboratories Ltd. has proposed a dividend after 23 years, highlighting the highest Profit After Tax (PAT) of Rs. 118 crore for FY25. It includes financial highlights such as revenue, EBITDA, PAT, and EPS growth, but it is not a full financial report. The document is addressed to stock exchanges for dissemination and is clearly labeled as a press release. It does not contain detailed financial statements or comprehensive analysis typical of an Annual Report (10-K) or Interim Report (IR). It is an announcement of dividend proposal and financial performance highlights, fitting the category of Notice of Dividend Amount (DIV). The document length is under 5,000 characters, and it is an announcement rather than a full report, so it is not a report publication announcement (RPA). Therefore, the best classification is Notice of Dividend Amount (DIV).
2025-05-13 English
Press Release
Earnings Release Classification · 95% confidence The document is a press release announcing that Morepen Laboratories' board has proposed a dividend after 23 years, highlighting the highest Profit After Tax (PAT) for FY25. It includes financial highlights such as revenue, EBITDA, PAT, and EPS for the fiscal year 2025. The document is addressed to stock exchanges and is intended for public dissemination. It does not contain detailed financial statements or comprehensive analysis typical of an Annual Report (10-K) or Interim Report (IR). It is also not a simple announcement of a report publication but a substantive announcement of financial results and dividend proposal. Given the nature of the content—initial announcement of quarterly/periodical financial results with key highlights and dividend proposal—it fits best under the Earnings Release (ER) category.
2025-05-13 English
Please find attached file.
Regulatory Filings
2025-05-12 English
Monitoring Agency Report
Capital/Financing Update Classification · 95% confidence The document is titled 'Monitoring Agency Report for the quarter ended 31st March 2025' and is addressed to stock exchanges pursuant to SEBI regulations related to the monitoring of proceeds from a Qualified Institutions Placement (QIP). It is issued by a Monitoring Agency (CARE Ratings Limited) appointed to monitor the utilization of issue proceeds. The report contains detailed information on the use of funds raised through the QIP, including cost of objects, progress in utilization, and certifications from Chartered Accountants. The document is 15,000 characters long and contains substantive financial and compliance data related to the quarter ended March 31, 2025. This is not a simple announcement or certification but a detailed monitoring report on capital utilization. The closest fitting category is 'Capital/Financing Update (CAP)' as it relates to monitoring the use of capital raised through a financing activity (QIP). It is not an Annual Report, Interim Report, or Regulatory Filing, nor is it a simple announcement or voting result. Therefore, the appropriate classification is CAP with high confidence.
2025-05-12 English
Please find attached the File
Capital/Financing Update Classification · 95% confidence The document is titled 'Monitoring Agency Report for the quarter ended 31st March 2025' and is addressed to stock exchanges pursuant to SEBI regulations related to the monitoring of proceeds from a Qualified Institutions Placement (QIP). It is issued by a Monitoring Agency (CARE Ratings Limited) appointed to monitor the utilization of issue proceeds. The report contains detailed information on the use of funds raised through the QIP, including certifications, progress on the objects of the issue, and comments from the monitoring agency and the board of directors. The document is about monitoring the use of capital raised and compliance with regulatory requirements related to capital raising, not a general financial report or earnings release. It is not an announcement of a report but the report itself, with substantive content and analysis. This fits the category of Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes, including monitoring reports on utilization of proceeds from capital raising activities.
2025-05-12 English
Please find attached the investor presentation-Q4 FY25
Investor Presentation Classification · 100% confidence The document is titled 'Investor Presentation – Q4’ FY25' and is addressed to stock exchanges with a subject line explicitly stating it is an investor presentation for the quarter and financial year ended March 31, 2025. The content includes business segment summaries, financial highlights, market positioning, and product information typical of an investor presentation. There is no indication that this is a full financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a brief earnings release or regulatory filing. The length (15,000 characters) and detailed content support it being a presentation rather than a short announcement or certification. Therefore, the document fits the category of an Investor Presentation (IP).
2025-05-12 English

Browse filings by year

16 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.